Verition Fund Management
MRSN

Verition Fund Management’s Mersana Therapeutics MRSN Stock Holding History

Verition Fund Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,472
Closed -$482K – 3578
2024
Q4 		$482K Sell
13,472
-38,658
-74% -$2M ﹤0.01% 2509
2024
Q3 		$2.46M Buy
52,130
+51,688
+11,694% +$2.28M 0.02% 1295
2024
Q2 		$22.2K Sell
442
-22,125
-98% -$1.6M ﹤0.01% 2861
2024
Q1 		$2.53M Buy
+22,567
New +$2.24M 0.02% 1080
2023
Q4 		– Sell
-6,538
Closed -$208K – 2575
2023
Q3 		$208K Buy
+6,538
New +$311K ﹤0.01% 1957
2022
Q4 		– Sell
-652
Closed -$110K – 2541
2022
Q3 		$110K Buy
+652
New +$106K ﹤0.01% 2609

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return